Abstract. Sleep disturbances in systemic lupus erythematosus (SLE) are not well understood. The restless legs syndrome (RLS) is one of the frequent occurring sleep disturbances in SLE. The aim of this study was to evaluate the prevalence of RLS and its characteristics in SLE. We evaluated, in a prospective case-control study, 26 patients with SLE and 26 patients without SLE in an age- and sex-matched control group. An RLS-positive diagnosis met International RLS Study Group (IRLSSG) criteria. We used standardized questionnaires, which included demographic data, medical history and sleep assessment. We used validated questionnaires and scales to assess sleep. There were 23/26 females (88.46%) in each group; the mean patient age in the SLE subgroup was 51.65 years, while in the control subgroup, 52.07 years (range 30-74). Nine (34.2%) patients had RLS-positive criteria in the SLE group and 2 (7.69%) of 26 in the control group. Eight out of 9 patients described RLS onset after SLE was diagnosed. In the SLE group, 8 cases were of moderate severity and 1 was considered mild. The control group had one mild and one moderate case of RLS. RLS prevalence in SLE is higher and the quality of sleep is poorer compared with the control group.

Introduction

Restless legs syndrome (RLS) includes various sensitive symptoms and is identified if following criteria are fulfilled: i) the need to move the feet; ii) the patient perceives this sensation as uncomfortable and unpleasant; iii) this sensation is relieved by movement; iv) a circadian rhythm was described, meaning that the unpleasant sensation starts at evening time, especially when the patient is in bed. The same sensation may appear during the daytime in advanced cases, especially in the periods of rest or inactivity (1,2). The consensus published on 2003 by the International RLS Study Group (IRLSSG) stipulates that all the above four criteria need to be met to establish the diagnosis (1). These criteria were updated in 2014 (2) by adding an additional diagnostic criteria, requiring that no other medical or behavioral condition may explain the appearance of the symptoms mentioned above (2).

The prevalence of RLS is approximately 10% in different epidemiological studies (3-5), with a predominance of females (3). Clinically significant RLS has an estimated prevalence of approximately 2.7%. Worldwide RLS is often underdiagnosed and is considered to significantly impair sleep and quality of life (4-7). According to Allen and colleagues, more than half of the RLS patients report at least one sleep impairment, for instance insomnia, sleep fragmentation or daytime sleepiness (6). RLS patients declare worse global quality of life and important impairments of mental and general physical status compared to healthy individuals or to patients with other conditions (6). There are several diseases/conditions which are suggested to increase the prevalence of RLS: Renal failure (8), kidney transplantation (9), rheumatoid arthritis (10), fibromyalgia (11), lung transplantation (12), migraine (13), ankylosing spondylitis (14) or multiple sclerosis (15). In pregnancy, the prevalence of RLS is also high, but in contrast with the aforementioned conditions, it has a good prognosis, remitting in few weeks/months after delivery (16). Yet, few studies have assessed RLS and sleep disturbances in systemic lupus erythematosus (SLE) (17,18).
Pharmacological treatment of RLS may include iron supplementation in cases of low serum ferritin levels, dopamine agonists as first-line therapeutic options and anticonvulsivants or opioids in refractory cases (10).

The aims of this study were: i) To determine the prevalence of RLS in SLE patients; ii) to evaluate the clinical phenotype of RLS in SLE patients; iii) to discover an association between RLS and sleep characteristics and iv) to assess sleep disturbances in these patients.

**Patients and methods**

**Design.** A prospective study was performed at the Departments of Immunology and Neurology of the County Emergency Clinic Hospital, Brașov, Romania, during the period June 2011-August 2013. This study enrolled 26 patients with SLE and 26 patients without SLE in an age- and sex-matched control group. No patient was previously diagnosed with RLS. The protocol for this study received acceptance from the Ethics Committee of the Transylvania University from Brașov (78/28.05.2011) and respects the ethical recommendations of the 1975 Declaration of Helsinki. Informed consent was signed by all subjects before recruitment. The study group consists of: i) consecutive patients with confirmed SLE diagnosed by an immunologist or rheumatologist; ii) patients older than 18 years of age; iii) able to sign an informed consent. The SLE patients presented with different affected organs but no central nervous system (CNS) involvement.

Exclusion criteria included: i) Uncertain SLE diagnosis; ii) medical or psychiatric comorbidities that could interfere with the diagnosis of RLS; iii) inability/refusal to provide study consent.

The control group included consecutive patients with no SLE. Among the symptoms, they presented low back pain with/without radicular syndrome or different types of headache.

**Assessments.** We collected demographic data, medical history, weight, height [for body mass index (BMI)] sleep and RLS assessment. A RLS-positive diagnosis was based on the four standardized criteria proposed by the International RLS Study Group (IRLSSG) as mentioned in the introduction (1). The assessment work included demographic data, medical history and history of the use of medications. The patients had to choose from a list of 21 terms which described the sensory sensations in their legs, according to Allen et al (1). The questionnaire comprised also questions related to sleep characteristics: Time to go to bed, time to wake up, number of hours that the subject sleeps.

The following scales were applied to both groups: Restless Legs Syndrome Rating-IRLS (19) to assess the severity of a patient's RLS symptoms; Restless Legs Syndrome Quality of Life Instrument (20); Pittsburg Sleep Quality Index (PSQI) (21); Epworth Sleepiness Scale (22). According to the Restless Legs Syndrome Rating Scale-IRLS (19), the scores for all items vary between 0 (without signs of RLS) to 4 (very intense RLS symptoms); the maximum score being 40. Therefore, according to the obtained scores, the categories of severity were: Mild, 1-10; moderate, 11-20); severe, 21-30; very severe, 31-40.

**Statistical analysis.** Statistical analysis was performed using Microsoft Excel 2010 software (Microsoft) and Matlab 2019b (MathWorks). Data are presented as the mean ± standard deviation. For demographics and clinical assessment, we used descriptive statistics. Statistical differences between groups were analyzed using the one-way ANOVA test of variance followed by the Tukey's post hoc test or student's t-test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Demographic data are presented in Table 1.** RLS+ represents all the patients fulfilling the RLS study group-positive criteria and RLS-were patients without RLS. The mean patient age was similar in the two groups: 51.65 years in patients with SLE and 52.07 years in patients without SLE (range 30-74). There were 9/26 patients (34.62%) who fulfilled RLS-positive criteria (RLS+) (positive answers to all the 4 diagnostic criteria questions) in the study group and 2/26 (7.69%) RLS+ patients in the control group (P<0.05). Family history was positive for 2 out of 9 patients with RLS in patients with SLE and none in the control group. We compared the characteristics of the patients in the study group with SLE and RLS (RLS+) with those from control group with RLS (RLS+). In the SLE and RLS+ group, compared with the control group with RLS (RLS+), we observed that the patients were older (mean age, 56.66±10.40 years vs. 48.5±0.7 years), predominantly females (7/9 vs. 2/2), with a higher prevalence of iron deficiency anemia (P<0.05).

According to our results, SLE patients reported more frequent and more intense symptoms of RLS compared to the control subgroup. RLS symptoms in the study group (n=9) had as frequency: 1 day/month in 1 patient, 1-2 days/week in 1 patient, 2-3 days/week in 2 patients, 4-5 days/week in 1 patient and daily in 4 patients. In the control group, one patient with RLS had daily symptoms and one had symptoms 1-2 days/week. In the study group, all participants with RLS, except one, described that the RLS symptoms became manifest after the diagnosis of SLE. The mean interval from the diagnosis of SLE and the occurrence of RLS was 3.3±2.2 years.

In the study group (n=9), the mean IRLS score (19) had the following distribution: Mild (0-10) in 1 case, moderate (11-20) in 8 cases. There were no cases considered appropriate from inclusion in the severe (21-30) or very severe (31-40) group. For the controls there was one mild case (0-10) and one moderate case (11-20).

We compared clinical and laboratory exams of the SLE study patients with (RLS+) and without RLS (RLS-). Female representation was 7/9 (77.77%) in the RLS+ vs. 16/17 (94.11%) in the RLS-group. There were 2 patients with polynuropathy and RLS+ in the SLE group but none with polynuropathy among RLS-. In the control group there were no polynuropathy cases. The SLE study group patients received standard treatment, according to the guidelines in use, depending on the disease severity: Non-steroidal anti-inflammatory drugs, corticosteroids, hydroxychloroquine, immunosuppressants, biological therapies. No patient was diagnosed previously with RLS and no specific treatment was administered.
Sleep characteristics are presented in Table II: Epworth Sleepiness Scale score, PSQI score, time to go to bed (hour:min), wake up time (hour:min), time in bed (hour:min), sleep duration (mean, hour). The sleep characteristics were comparatively analyzed in the study and control group. PSQI score (higher in the RLS+ subgroup, \(P=0.03\)), time to wake up (earlier in the RLS+ subgroup, \(P=0.04\)) and sleep duration (less in the RLS+ subgroup, \(P=0.03\)) reached statistical significance between the study and control groups.

Excessive daytime sleepiness [Epworth Sleepiness Scale score (ESS) >10] was not reported by any patient. ESS score of 6‑10 was reported by 69.23% vs. 46.15% (\(P=0.01\)) in the two groups.

**Discussion**

This study shows a higher prevalence of restless legs syndrome (RLS) in systemic lupus erythematosus (SLE) patients (34.62%) compared with controls (7.69%). The RLS prevalence in the SLE group was higher compared with the one reported in the general population, which varies at approximately 10% (4.5). Hassan *et al* (17) showed that 12 of 33 (36.36%) patients with SLE had RLS compared with 4 of 32 control patients (12.5%). Kucuk *et al* (18) also suggested a high prevalence of RLS in SLE patients (30.6% vs. 4.8%). Even if RLS prevalence appears to be higher in SLE patients, the pathological mechanisms remain unclear. Possible explanations include genetic susceptibility and the existence of antibodies against dopaminergic cells in SLE which disturb the dopaminergic functionality, therefore increasing the risk of RLS occurrence in these patients (17). Anemia is reported as a risk factor for RLS prevalence and severity (18). Iron deficiency anemia was more prevalent in our study in the SLE group. Due to our limited sample, we were unable to demonstrate an association between RLS and anemia, as shown by Kucuk *et al* (18).

The presence of RLS in systemic lupus erythematosus (SLE) impacts the quality of sleep; higher PSQI scores (meaning poorer sleep quality), earlier time to wake up and shorter total sleep time were reported.

There is limited available information regarding sleep disturbances in SLE patients with RLS, but considering the potential impairment of sleep quality induced by RLS, further studies (including also objective sleep assessments) are required.

There are some limitations in our study: i) Enrollment of a population visiting the hospital clinic could have added more
comorbidities and thus more potential factors involved in the leg sensations; and ii) electromyography and nerve conduction studies were not performed in any patient. Hence, the two patients had clinical polyneuropathy.

In conclusion, the present study showed that SLE patients reported a higher prevalence of RLS, most of them being females. An association between RLS and iron-deficiency anemia was identified in the study group. The majority of our patients reported mild or moderate RLS symptoms, occurring in 58% of cases in more than 4 nights per week. The co-occurrence of polyneuropathy in two of our patients may have influenced the perceived severity of the clinical manifestations of RLS. The existence of RLS symptoms in SLE patients correlated with the impairment of sleep parameters, in contrast with SLE patients without RLS.

Acknowledgements

This manuscript was partially presented as an e-poster at the 3rd European Academy of Neurology Congress, June 2017, Amsterdam.

Funding

No funding was received.

Availability of data and materials

Available upon reasonable request.

Authors’ contributions

All the authors substantially contributed to each of the following aspects of this paper. CFP performed the design and conception of the study, recruited the patients, analyzed and interpreted the data, and drafted the manuscript. AE recruited the patients, analyzed and interpreted the data, and critical revised the manuscript for important intellectually content. CF recruited the patients, analyzed and interpreted the data, and drafted the manuscript. OFP analyzed and interpreted the data, and critical revised the manuscript. SD aided in the literature review, analyzed and interpreted the data, and critical revised the manuscript for important intellectually content. VM analyzed and interpreted the data, and critical revised the manuscript for important intellectually content. OFP analyzed and interpreted the data, and critical revised the manuscript for important intellectually content. CF recruited the patients, analyzed and interpreted the data, and critical revised the manuscript for important intellectually content. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Approval for the present study was provided by the Ethics Committee of the Transilvania University from Brașov, Romania. Patient consent was not needed as the database was anonymized.

Patient consent for publication

Not applicable.

Competing interests

All the authors declare that they have no competing interests.

Authors’ information

ORCID ID: Cristian Falup-Pecurariu: 0000-0002-7394-7161; Anca Enache: 0000-0002-4647-5939; Liliana Duca: 0000-0002-3062-766X; Camil Foteșcu: 0000-0002-3251-6947; Oana Falup-Pecurariu: 0000-0003-1972-6859; Vlad Moneșcu: 0000-0002-0506-931X; Stefania Diaconu: 0000-0002-0251-4043; Carmen Adella Sirbu: 0000-0002-1982-1066.

References


